Newsroom | 210535 results

WASHINGTON--(BUSINESS WIRE)--CMMI has disrupted patient access, undermined providers, operated with little accountability, and wasted billions of taxpayer dollars....

ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company’s talc products exposed her to asbestos and contributed to her developing peritoneal mesothelioma, a cancer of the peritoneal lining in the stomach. The verdict follows a 13-day trial in Ramsey County District Court, where jurors heard evidence that Johnson & Johnson sold an...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares will cease trading on the NYSE American at market close...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Podcast and YouTube participation rises dramatically at the Global Healthy Living Foundation...

シアトル--(BUSINESS WIRE)--（ビジネスワイヤ） -- スケーラブルで利用しやすい単一細胞シーケンシングソリューションの主要プロバイダーであるパース・バイオサイエンシズ（Parse Biosciences）は、Codebreaker Labsとの協業を発表しました。本協業では、数千の遺伝子バリアントを並列に評価し、その影響を単一細胞解像度で測定できる画期的なプラットフォームを開発・検証します。Codebreakerの合成生物学プラットフォームおよびバリアントエンジニアリングの能力を、パース・バイオサイエンシズのEvercode™技術が持つ拡張性や導入の容易さと組み合わせることで、AI開発者、創薬チーム、そして臨床研究者の間で需要が高まりつつある因果データの創出を目指しています。 現在のゲノミクス研究は、観察データ（大規模集団の中で確認されるバリアント）に大きく依存しています。しかし、一部の個人または限られた家系内でのみ見られることが多い希少バリアントやプライベートバリアントは、統計的に意味のある結論を導くのに十分な保有者数が存在しないため、この方法では解析がほぼ不可能...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--FDA has qualified the first surrogate endpoint for bone fractures in anti-osteoporosis drug trials for at-risk post-menopausal women....

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity award...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, der führende Anbieter skalierbarer, zugänglicher Lösungen für die Einzelzell-Sequenzierung, gab heute eine Zusammenarbeit mit Codebreaker Labs bekannt, um eine bahnbrechende Plattform, die Tausende genetischer Varianten parallel testen und deren Auswirkungen mit Einzelzellauflösung messen kann, zu entwickeln und zu validieren. Durch die Kombination von Codebreakers Plattform für synthetische Biologie sowie dessen Fähigkeiten im Variant Engineering mi...

DUBLIN--(BUSINESS WIRE)--The "ENT Disorder Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The ENT disorder treatment market is experiencing rapid transformation as organizations adopt new medical technologies and evolving care models to address complex clinical and operational challenges. Senior decision-makers are seeking strategies that enable both enhanced patient outcomes and sustainable organizational performance in this dynamic he...

DUBLIN--(BUSINESS WIRE)--The "Thyroid Eye Disease Treatments Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The thyroid eye disease treatments market is undergoing substantial transformation, fueled by new therapies, advanced diagnostics, and evolving care pathways. As a complex autoimmune disorder, thyroid eye disease challenges health systems and presents significant opportunities for innovation and patient-centered solutions. Market Snapshot:...